Man Group’s Theravance Biopharma TBPH Stock Holding History

Man Group’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$690K	Sell	40,613 -1,490	-4%	-$24.7K	﹤0.01%	1972
2026 Q1	$683K	Sell	42,103 -74,981	-64%	-$1.33M	﹤0.01%	1973
2025 Q4	$2.19M	Buy	117,084 +37,293	+47%	+$619K	﹤0.01%	1419
2025 Q3	$1.16M	Buy	+79,791	New	+$1.01M	﹤0.01%	1619
2025 Q1	–	Sell	-10,328	Closed	-$97.2K	–	2362
2024 Q4	$97.2K	Sell	10,328 -14,851	-59%	-$135K	﹤0.01%	1928
2024 Q3	$203K	Buy	+25,179	New	+$218K	﹤0.01%	1854
2024 Q2	–	Sell	-10,101	Closed	-$90.6K	–	2264
2024 Q1	$90.6K	Sell	10,101 -24,271	-71%	-$225K	﹤0.01%	2071
2023 Q4	$386K	Buy	+34,372	New	+$346K	﹤0.01%	1754
2018 Q4	–	Sell	-8,942	Closed	-$292K	–	2104
2018 Q3	$292K	Buy	+8,942	New	+$244K	﹤0.01%	1964

Other funds holding TBPH

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

ICM

Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Man Group's TBPH Position: Q2 2026 in Review

Man Group reduced its Theravance Biopharma (TBPH) stake by 3.5% in Q2 2026, selling an estimated $24.7K and leaving 40,613 shares worth $690K. The position accounts for ﹤0.01% of the portfolio, ranked #1972.

Man Group first reported a position in TBPH in Q3 2018 and has held it in 9 quarters since. The position peaked at $2.19M in Q4 2025. 179 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

Man Group held 40,613 shares of Theravance Biopharma worth $690K as of Q2 2026.
Man Group sold 1,490 Theravance Biopharma shares in Q2 2026, an estimated $24.7K.
Theravance Biopharma made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #1972 holding.
Man Group first reported a position in Theravance Biopharma in Q3 2018 and has held it in 9 quarters since.
Man Group's Theravance Biopharma position peaked at $2.19M in Q4 2025.
179 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.